PMID: 9540133Apr 16, 1998Paper

Beta-adrenergic blockade in chronic heart failure

Scandinavian Cardiovascular Journal. Supplement
M R Bristow, J D Port

Abstract

In summary, beta-blockade is currently the most promising "new" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.

References

Oct 1, 1975·British Heart Journal·F WaagsteinI Wallentin
Aug 1, 1991·Circulation·B Kennedy, M G Ziegler
Jul 1, 1988·The Journal of Clinical Investigation·A M FeldmanC Van Dop
Apr 26, 1985·The American Journal of Cardiology·M B Fowler, M R Bristow
Jul 1, 1985·Journal of Molecular and Cellular Cardiology·M R BristowM B Fowler
Aug 1, 1980·British Heart Journal·K SwedbergI Wallentin
Jul 22, 1982·The New England Journal of Medicine·M R BristowE B Stinson
Sep 27, 1984·The New England Journal of Medicine·M R Bristow
Nov 1, 1995·Journal of the American College of Cardiology·D M KayeM D Esler
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·C A MilanoR J Lefkowitz
Dec 1, 1993·The Journal of Clinical Investigation·M R BristowA M Feldman
Nov 1, 1995·European Heart Journal·M R Bristow, W T Abraham
Feb 1, 1997·Journal of the American College of Cardiology·A Marmor, A Schneeweiss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.